Article Page

Abstract

As one of the main factors limiting the accuracy of MD results is the empirical force field used, the present paper offers a review of recent developments in the CHARMM additive force field, one of the most popular bimolecular force fields. Additionally, we present a detailed discussion of the CHARMM Drude polarizable force field, anticipating a growth in the importance and utilization of polarizable force fields in the near future. Throughout the discussion emphasis is placed on the force fields’ parametrization philosophy and methodology.CHARMM additive and polarizable force fields for biophysics and computer-aided drug design An in silico KIF20A-derived Peptide agonistic mimicking sited and computer-aided designed poly-chemo-scaffold as an innovative drug-like molecule comprising potential clinical hyper-inhibitor properties in Patients With Advanced Pancreatic Cancer when combined with Gemcitabine. Success and Incoherence of Orthodox Quantum Mechanics. Orthodox quantum mechanics is a highly successful theory despite its serious conceptual flaws. It renounces realism, implies a kind of action-at-a-distance and is incompatible with determinism. Orthodox quantum mechanics states that Schrödinger’s equation (a deterministic law) governs spontaneous processes while measurement processes are ruled by probability laws. It is well established that time dependent perturbation theory must be used for solving problems involving time. In order to account for spontaneous processes, this last theory makes use of laws valid only when measurements are performed. This incoherence seems absent from the literature. KIF20A (RAB6KIFL) belongs to the kinesin superfamilyof motor proteins, which play critical roles in the traffickingof molecules and organelles during the growth of pancreatic cancer.Immunotherapy using a previously identified epitope peptide forKIF20A is expected to improve clinical outcomes. A phase I clinicaltrial combining KIF20A-derived peptide with gemcitabine (GEM) was therefore conducted among patients with advancedpancreatic cancer who had received prior therapy such as chemotherapyand/or radiotherapy. Despite, huge importance of the field, no dedicated AVP resource is available. In the present Research Scientific Project , we have collected 1245 peptides with antiviral activity targeting important human viruses like influenza, HIV, HCV and SARS, etc. After removing redundant peptides, 1056 peptides were divided into 951 training and 105 validation data sets. We have exploited various peptides sequence features, i.e. motifs and alignment followed by amino acid composition and physicochemical properties during 5-fold cross validation using Computer-aided CHARMM additive drug design and Orthodox Quantum Mechanics polarizable force fields for biophysics Success and Incoherence of an in silico KIF20A-derived Peptide agonistic mimicking sited designed poly-chemo-scaffold as an innovative drug-like molecule with potential clinical hyper-inhibitor properties in Gemcitabine treated Patients With Advanced Pancreatic Cancer.

Keywords

CHARMM additive; polarizable force fields; biophysics; computer-aided drug design; in silico KIF20A-derived Peptide; agonistic mimicking; computer-aided designed; poly-chemo-scaffold; innovative drug-like molecule; clinical hyper-inhibitor properties; Patients With Advanced Pancreatic Cancer; Success and Incoherence; Orthodox Quantum Mechanics.

Article Type

Research Article – Abstract

Publication history

Received: Sep 20, 2017
Accepted: Sep 25, 2017
Published: Oct 01, 2017

Citation

Grigoriadis Ioannis, Grigoriadis George, Grigoriadis Nikolaos, George Galazios (2017) Computer-aided CHARMM additive drug design and Orthodox Quantum Mechanics polarizable force fields for biophysics Success and Incoherence of an in silico KIF20A-derived Peptide agonistic mimicking sited designed poly-chemo-scaffold as an innovative drug-like molecule with potential clinical hyper-inhibitor properties in Gemcitabine treated Patients With Advanced Pancreatic Cancer.

Authors Info

Grigoriadis Nikolaos
Department of IT Computer Aided Personalized Myoncotherapy, Cartigenea-Cardiogenea, Neurogenea-Cellgenea, Cordigenea-HyperoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis Ioannis
Department of Computer Drug Discovery Science, BiogenetoligandorolTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

Grigoriadis George
Department of Stem Cell Bank and ViroGeneaTM,
Biogenea Pharmaceuticals Ltd,
Thessaloniki, Greece;

George Galazios
Professor of Obstetrics and Gynecology,
Democritus University of Thrace,
Komotini, Greece;

E-mail: biogeneadrug@gmail.com

File not available